Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients
Status: | Completed |
---|---|
Conditions: | Hospital, Pulmonary |
Therapuetic Areas: | Pulmonary / Respiratory Diseases, Other |
Healthy: | No |
Age Range: | 12 - Any |
Updated: | 5/5/2014 |
Start Date: | March 2013 |
End Date: | September 2014 |
Contact: | Taneli Jouhikainen, M.D. |
Phone: | (888) 302-4876 |
A Phase 2, Randomized, Double Blind, Placebo-controlled Study of AeroVanc for the Treatment of Persistent Methicillin-resistant Staphylococcus Aureus Lung Infection in Cystic Fibrosis Patients
The purpose of this study is to determine whether AeroVanc treatment is safe and effective
in reducing the number of MRSA colony forming units in the lungs of cystic fibrosis
patients.
in reducing the number of MRSA colony forming units in the lungs of cystic fibrosis
patients.
This is a Phase 2a randomized, multicenter, double-blind, placebo-controlled, parallel group
study to examine the safety and efficacy of AeroVanc in the treatment of persistent MRSA
lung infection in CF patients. Pharmacokinetics will be evaluated in a subgroup by measuring
plasma and sputum concentrations of vancomycin.
Prior to treatment, patients will be randomized to receive either AeroVanc twice daily
(bid), or placebo bid. Patients will be stratified based on the presence of a Pseudomonas
aeruginosa (P. aeruginosa) co-infection that is being treated with a chronic suppression
regimen. Patients with P. aeruginosa co-infection can be on any chronic inhaled suppression
regimen (or nothing if the patient is considered stable in the opinion of the investigator
despite the lack of treatment). Regardless of treatment regimen, if there is an off month,
screening should be scheduled so that AeroVanc or placebo administration can be given during
this time. Patients with no off month should be screened so that the AeroVanc or placebo
administration period coincides with a treatment cycle other than TOBI (e.g., Cayston or
colistin). All patients must have at least a 24-hour washout period after stopping their
anti-Pseudomonas therapy and prior to the Visit 2 (Baseline) pre-dose microbiology sputum
sample. The AeroVanc or placebo treatment duration is 28 days, during which efficacy and
safety parameters will be measured, and after which patients will be followed up for 56
days.
There will be two treatment cohorts in this study, each comprised of 40 randomized (1:1
active to placebo) and treated patients (adults ≥18 and children ≥12 years of age). In
Cohort 1, patients will be enrolled and randomized to receive the 32 mg dose of AeroVanc bid
or placebo bid. Prior to starting enrollment in Cohort 2, a safety evaluation will be
carried out by the Data Monitoring Committee (DMC) based on treatment data from the first 20
patients in Cohort 1. Subject to the Sponsor's written communication of the DMC's opinion of
acceptable safety, the dose for the active arm in Cohort 2 will be escalated to 64 mg bid.
Optionally, the active arm for Cohort 2 may also be kept the same (32 mg bid), or reduced to
16 mg bid, depending on the outcome of the DMC's safety evaluation.
study to examine the safety and efficacy of AeroVanc in the treatment of persistent MRSA
lung infection in CF patients. Pharmacokinetics will be evaluated in a subgroup by measuring
plasma and sputum concentrations of vancomycin.
Prior to treatment, patients will be randomized to receive either AeroVanc twice daily
(bid), or placebo bid. Patients will be stratified based on the presence of a Pseudomonas
aeruginosa (P. aeruginosa) co-infection that is being treated with a chronic suppression
regimen. Patients with P. aeruginosa co-infection can be on any chronic inhaled suppression
regimen (or nothing if the patient is considered stable in the opinion of the investigator
despite the lack of treatment). Regardless of treatment regimen, if there is an off month,
screening should be scheduled so that AeroVanc or placebo administration can be given during
this time. Patients with no off month should be screened so that the AeroVanc or placebo
administration period coincides with a treatment cycle other than TOBI (e.g., Cayston or
colistin). All patients must have at least a 24-hour washout period after stopping their
anti-Pseudomonas therapy and prior to the Visit 2 (Baseline) pre-dose microbiology sputum
sample. The AeroVanc or placebo treatment duration is 28 days, during which efficacy and
safety parameters will be measured, and after which patients will be followed up for 56
days.
There will be two treatment cohorts in this study, each comprised of 40 randomized (1:1
active to placebo) and treated patients (adults ≥18 and children ≥12 years of age). In
Cohort 1, patients will be enrolled and randomized to receive the 32 mg dose of AeroVanc bid
or placebo bid. Prior to starting enrollment in Cohort 2, a safety evaluation will be
carried out by the Data Monitoring Committee (DMC) based on treatment data from the first 20
patients in Cohort 1. Subject to the Sponsor's written communication of the DMC's opinion of
acceptable safety, the dose for the active arm in Cohort 2 will be escalated to 64 mg bid.
Optionally, the active arm for Cohort 2 may also be kept the same (32 mg bid), or reduced to
16 mg bid, depending on the outcome of the DMC's safety evaluation.
Inclusion Criteria:
1. Adults ≥18 years old (and the legally authorized representatives of children ≥12 but
<18 years old): Able to communicate with site personnel and to understand and
voluntarily sign the Informed Consent Form (ICF). Children ≥12 but <18 years old:
Able to communicate with site personnel and to understand and voluntarily sign the
Assent Form.
2. Able and willing to comply with the protocol, including availability for all
scheduled study visits.
3. Have a confirmed diagnosis of CF, determined by having clinical features consistent
with the CF phenotype, plus one of the following: a) Positive sweat chloride test
(value ≥60 mEq/L), or b) Genotype with two mutations consistent with CF (ie, a
mutation in each of the cystic fibrosis transmembrane conductance regulator [CFTR]
genes).
4. Be ≥12 years old at time of ICF/Assent Form signing.
5. Have sputum culture positive for MRSA at Screening, with at least 10,000 CFUs/mL of
MRSA.
6. In addition to the screening sample, have at least two historical respiratory tract
cultures (i.e., sputum and/or throat swab) positive for MRSA prior to Screening and
evidence that the MRSA lung infection has persisted for at least 6 months prior to
Screening.
7. Have forced expiratory volume in 1 second (FEV1) ≥30% and ≤100% of predicted that is
normalized for age, gender, and height at Screening.
8. Evidence, defined as one or both of the following, that the persistent MRSA lung
infection is suspected to be causing health consequences.
- Have had at least one episode of acute pulmonary infection treated with
non-maintenance antibiotics within 12 months from Screening. Initiation of
treatment with intermittent inhaled anti-Pseudomonas therapy will not qualify as
treatment with non-maintenance antibiotics.
- Requires anti-MRSA treatment as part of a maintenance regimen to prevent
pulmonary exacerbations or other respiratory symptoms.
9. Be able to perform all the techniques necessary to use the AeroVanc inhaler and
measure lung function.
10. Be able to produce expectorated sputum samples or be able and willing to undergo
standardized sputum induction.
11. Agree not to smoke from Screening through the end of the study.
12. Female patients of child-bearing potential are eligible to participate in this study
only if they are NOT pregnant or lactating, and if the patient is using a highly
effective method of birth control.
13. Patients with P. aeruginosa co-infection must either be stable on a regular
suppression regimen of inhaled antibiotics or must be, in the opinion of the
investigator, stable despite the lack of such treatment. Patients on a Cayston based
therapy must have received at least 2 cycles of Cayston prior to Baseline (can be 2
consecutive months or 2 cycles over 4 months).
Exclusion Criteria:
1. Administration of any investigational drug or device within 28 days prior to
ICF/Assent Form signing.
2. Use of iv or inhaled anti-MRSA drugs within 28 days or oral anti-MRSA drugs within 14
days prior to Visit 2 (ie, randomization, Baseline and AeroVanc/placebo treatment
initiation).
3. A history of previous allergies or sensitivity to vancomycin, or other component(s)
of the study drug or placebo except for a history of red-man syndrome.
4. History of severe cough/bronchospasm upon inhalation of dry powder inhalation
product, or nebulized vancomycin.
5. Resistance to vancomycin at Screening (vancomycin resistant Staphylococcus aureus
[VRSA], or vancomycin intermediate resistant Staphylococcus aureus [VISA], with
minimum inhibitory concentration [MIC] ≥4 mcg/mL).
6. Oral corticosteroids in doses exceeding 10 mg prednisone per day or 20 mg prednisone
every other day, or equipotent doses of another corticosteroid.
7. History of sputum culture or throat swab culture yielding B. cepacia or gladioli in
the previous two years, or nontuberculosis mycobacteria in the previous six months.
8. An acute upper or lower respiratory infection, or pulmonary exacerbation within 7
days prior to Randomization.
9. Changes in antimicrobial, bronchodilator, anti-inflammatory or corticosteroid
medications within 7 days prior to ICF/Assent Form signing.
10. Current daily continuous oxygen supplementation or requirement for more than 2 L/min
at night.
11. Changes in physiotherapy technique or schedule within 7 days prior to ICF/Assent Form
signing.
12. History of lung or other solid organ transplantation or currently on the list to
receive lung or other solid organ transplantation.
13. A chest X-Ray at Screening with abnormalities indicating a significant acute finding
(eg, pneumothorax, or pleural effusion).
14. Lactating female or female with a positive pregnancy test result. All women of
childbearing potential will be tested.
15. Renal insufficiency, defined as creatinine clearance <50 mL/min using the
Cockcroft-Gault equation for adults or Schwartz equation in children, at Screening.
16. Diagnosed with clinically significant hearing loss.
17. Abnormal liver function, defined as ≥4x upper limit of normal (ULN), of serum
aspartate aminotransferase (AST) or serum alanine aminotransferase (ALT), or known
cirrhosis at the time of Screening.
18. Serum hematology or chemistry screening results which in the judgment of the
Investigator would interfere with completion of the study.
19. Positive for human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis
C virus (HCV).
20. Other findings or medical history at screening that, in the Investigator's opinion,
would compromise the safety of the patient or the quality of the study data.
We found this trial at
42
sites
1601 Northwest 12th Avenue
Miami, Florida 33136
Miami, Florida 33136
(305) 243-6545
University of Miami Miller School of Medicine The University of Miami Leonard M. Miller School...
Click here to add this to my saved trials
4900 Mueller Boulevard
Austin, Texas 78723
Austin, Texas 78723
(512) 324-0000
Dell Children's Medical Center of Central Texas Welcome to Dell Children
Click here to add this to my saved trials
Nationwide Children's Hospital At Nationwide Children’s, we are creating the future of pediatric health care....
Click here to add this to my saved trials
Click here to add this to my saved trials
1211 Medical Center Dr
Nashville, Tennessee 37232
Nashville, Tennessee 37232
(615) 322-5000
Vanderbilt Univ Med Ctr Vanderbilt University Medical Center (VUMC) is a comprehensive healthcare facility dedicated...
Click here to add this to my saved trials
Click here to add this to my saved trials
4401 Penn Avenue
Pittsburgh, Pennsylvania 15224
Pittsburgh, Pennsylvania 15224
412-692-5325
Children's Hospital of Pittsburgh of UPMC UPMC is one of the leading nonprofit health systems...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Univ of North Carolina Carolina’s vibrant people and programs attest to the University’s long-standing place...
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
Charleston, South Carolina 29425
843-792-1414
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
Click here to add this to my saved trials
225 E Chicago Ave
Chicago, Illinois 60611
Chicago, Illinois 60611
(312) 227-4000
Ann & Robert H. Lurie Children's Hospital of Chicago Ann & Robert H. Lurie Children
Click here to add this to my saved trials
303 E Chicago Ave
Chicago, Illinois 60611
Chicago, Illinois 60611
(312) 503-8194
Northwestern University Feinberg School of Medicine Northwestern University Feinberg School of Medicine, founded in 1859,...
Click here to add this to my saved trials
Cleveland, Ohio 44106
Click here to add this to my saved trials
University of Texas Southwestern Medical Center UT Southwestern is an academic medical center, world-renowned for...
Click here to add this to my saved trials
Dayton Children's - Dayton We have more than 290,000 reasons to make sure the care...
Click here to add this to my saved trials
National Jewish Health National Jewish Health is known worldwide for treatment of patients with respiratory,...
Click here to add this to my saved trials
Click here to add this to my saved trials
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
University of Kansas Medical Center The University of Kansas Medical Center serves Kansas through excellence...
Click here to add this to my saved trials
The University of California, San Diego UC San Diego is an academic powerhouse and economic...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
University of Louisville The University of Louisville is a state supported research university located in...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
Saint Louis, Missouri 63110
(314) 362-5000
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
Click here to add this to my saved trials
Click here to add this to my saved trials
University of Washington Medical Center University of Washington Medical Center is one of the nation's...
Click here to add this to my saved trials
Click here to add this to my saved trials
Tampa, Florida 33606
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials